King Luther Capital Management Corp Takes Position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB)

King Luther Capital Management Corp acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 59,662 shares of the company’s stock, valued at approximately $100,000. King Luther Capital Management Corp owned about 0.23% of Anebulo Pharmaceuticals at the end of the most recent quarter.

Analyst Ratings Changes

Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 target price on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

Anebulo Pharmaceuticals Price Performance

NASDAQ ANEB opened at $1.71 on Friday. The stock has a market capitalization of $70.26 million, a P/E ratio of -6.11 and a beta of -1.09. The firm’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.63. Anebulo Pharmaceuticals, Inc. has a 12 month low of $0.80 and a 12 month high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings data on Friday, February 14th. The company reported ($0.09) EPS for the quarter. As a group, analysts anticipate that Anebulo Pharmaceuticals, Inc. will post -0.52 EPS for the current year.

Insiders Place Their Bets

In other news, Director Aron R. English acquired 10,101,010 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the acquisition, the director now owns 15,467,300 shares of the company’s stock, valued at $15,312,627. This represents a 188.23 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 85.90% of the stock is owned by insiders.

Anebulo Pharmaceuticals Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.